Chenghua Xia
Impact in
- Oncology top 5%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
-
- Melanoma and MAPK Pathways 3
- Renal and related cancers 3
-
- Renal cell carcinoma treatment 3
- Co-authors
- Walter M. Stadler (3 shared papers)Keith T. Flaherty (3 shared papers)Peter J. O’Dwyer (3 shared papers)Ronit Simantov (2 shared papers)Eric K. Rowinsky (2 shared papers)Mark J. Ratain (2 shared papers)Henry Q. Xiong (1 shared paper)Stan B. Kaye (1 shared paper)
- Journals
- Journal of Clinical Oncology (5 papers)Clinical Cancer Research (2 papers)Cancer (1 paper)Investigational New Drugs (1 paper)The Journal of Clinical Pharmacology (1 paper)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Chenghua Xia
11 papers receiving 1.9k citations
Chenghua Xia's Hit Papers
Peers
Comparison fields: 5 of 81
- Oncology 950
- Cancer Research 468
- Pulmonary and Respiratory Medicine 843
- Molecular Biology 1.2k
- Hepatology 94
Countries citing papers authored by Chenghua Xia
This map shows the geographic impact of Chenghua Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenghua Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenghua Xia more than expected).
Fields of papers citing papers by Chenghua Xia
This network shows the impact of papers produced by Chenghua Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenghua Xia. The network helps show where Chenghua Xia may publish in the future.
Co-authors
The 25 scholars most cited alongside Chenghua Xia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 794 |
| 2 | 2009 | 415 | |
| 3 | 2010 | 193 | |
| 4 | 2008 | 182 | |
| 5 | 2008 | 118 | |
| 6 | 2007 | 81 | |
| 7 | 2003 | 74 | |
| 8 | 2009 | 40 | |
| 9 | 2010 | 33 | |
| 10 | 2018 | 13 | |
| 11 | 2018 | 1 |
About Chenghua Xia
Chenghua Xia is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Economics and Econometrics and Infectious Diseases, having authored 11 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (3 papers), Melanoma and MAPK Pathways (3 papers), Renal and related cancers (3 papers), Renal cell carcinoma treatment (3 papers), Economic and Financial Impacts of Cancer (2 papers), HER2/EGFR in Cancer Research (2 papers), Cancer Genomics and Diagnostics (1 paper) and Lymphoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Oncology (950 citations), Cancer Research (468 citations), Pulmonary and Respiratory Medicine (843 citations), Molecular Biology (1.2k citations) and Hepatology (94 citations). Chenghua Xia has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Walter M. Stadler, Keith T. Flaherty, Peter J. O’Dwyer, Ronit Simantov, Eric K. Rowinsky, Mark J. Ratain, Henry Q. Xiong, Stan B. Kaye, Apurva A. Desai and Amita Patnaik. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer, Investigational New Drugs and The Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.